Brought to you by 
Gardedam Therapeutics gets public listing, changes name after merger with Canadian shell
05 Jan 2016
Executive Summary
As a vehicle to go public, Gardedam Therapeutics Inc. (chaperone therapeutics for neurodegenerative diseases) is acquiring public Canadian shell company Lion Consulting Group Inc. through a reverse merger. The combined company changed its name to Cantabio Pharmaceuticals Inc., which will now operate under that name and trade on the OTC exchange under the symbol CTBO.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Drug Discovery Tools
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Payment Includes Stock
- Reverse Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com